Travere's FILSPARI misses eGFR total slope endpoint but achieves chronic slope significance in IgAN

Travere Therapeutics, Inc.

eGFR total slope difference vs irbesartan 1.0 mL/min/1.73m2 per year, p=0.058 (missed statistical significance).
eGFR chronic slope difference 1.1 mL/min/1.73m2 per year, p=0.037 (statistically significant).
Company to submit sNDA for full FDA approval of FILSPARI in IgAN in first half of 2024.
EU CMA decision for sparsentan in IgAN expected from CHMP around end of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.